• KOLs Community
    • Hyperviscosity
    • Hyperviscosity Syndrome
    • Robert A O'reilly
    • Robert A O'Reilly

      Robert A O'Reilly

      Department of Medicine, Santa Clara County Hospital, San Jose, and the School of Medicine, University of California at San Francisco



      KOL Resume for Robert A O'Reilly


      Department of Medicine, Santa Clara County Hospital, San Jose, and the School of Medicine, University of California at San Francisco



      Robert A O'Reilly: Influence Statistics

      Sample of concepts for which Robert A O'Reilly is among the top experts in the world.
      Concept World rank
      warfarin metronidazole #1
      metronidazole stereoselective #1
      longterm therapy swarfarin #1
      daily phenylbutazone 300 #1
      ranitidine substituted imidazoles #1
      anticoagulant ranitidine #1
      pyrazolons coumarin #1
      stereoselective interaction trimethoprimsulfamethoxazole #1
      400 phenprocoumon #1
      interactions normal subjects #1
      sulfinpyrazone interaction #1
      phenylbutazone sulfinpyrazone interaction #1
      racemic phenprocoumon 06 #1
      commercial racemic warfarin #1
      sulfinpyrazone prothrombin time #1
      swarfarin amounts #1
      coumarin anticoagulant phenprocoumon #1
      hypoprothrombinemia blood samples #1
      06 daily phenylbutazone #1
      racemic occurred #1
      hypoprothrombinemia metronidazole #1
      racemic warfarin metronidazole #1
      interaction racemic warfarin #1
      anticoagulant phenprocoumon interactions #1
      warfarin concentrations cimetidine #1
      amounts kilogram #1
      daily hypoprothrombinemia #1
      300 day warfarin #1
      prothrombin sulfinpyrazone #1
      cimetidine hypoprothrombinemia #1
      metronidazole occurred #1
      ranitidine racemic #1
      hypoprothrombinemia blood concentrations #1
      hypoprothrombinemia blood #1
      racemic warfarin cimetidine #1
      warfarin ranitidine #1
      ranitidine racemic warfarin #1
      trimethoprimsulfamethoxazole separated enantiomorphs #1
      sulfinpyrazone 400 #1
      mouth warfarin #1
      metronidazole prothrombin #1
      oral anticoagulant phenprocoumon #1
      phenprocoumon interactions #1
      phenprocoumon content #1
      ranitidine stereoisomerism warfarin #1
      metronidazole interaction #1
      anticoagulant warfarin sodium #1
      prothrombin time sulfinpyrazone #1
      phenprocoumon 14 #1
      hypoprothrombinemia daily #2


      Prominent publications by Robert A O'Reilly

      KOL-Index: 9159

      The interaction of the anticoagulant drug warfarin and its metabolites with human plasma albumin was studied by equilibrium dialysis. A 20-fold variation of buffer ionic strength (0.017-0.340) caused no significant change in the warfarin association constant. But the binding strength rose significantly as the pH was increased from 6.0 to 9.0 and then declined at pH 10.0. The 6-, 7-, and 8-hydroxywarfarin metabolites showed a 7- to 23-fold reduction in binding strength at pH 10.0. These ...

      Known for Plasma Albumin | Binding Warfarin | Molecular Basis | Equilibrium Dialysis | Hydrophobic Bonding
      KOL-Index: 5678

      Cimetidine potentiates the anticoagulant effect of warfarin sodium, but in one small study ranitidine hydrochloride did not. Furthermore, these drugs have not been compared in the same subjects. Eleven normal subjects received single oral doses of 1.5 mg/kg racemic warfarin sodium alone, with cimetidine (1,200 mg/day orally), or with ranitidine (300 mg/day orally), beginning three days before the warfarin and daily thereafter for the duration of hypoprothrombinemia. Blood samples were ...

      Known for Cimetidine Ranitidine | Racemic Warfarin | H2receptor Antagonists | Single Oral Doses | Determination Prothrombin
      KOL-Index: 5631

      Because of the known interaction of warfarin and disulfiram and the "disulfiram effect" of metronidazole, the interaction with metronidazole of commercial racemic warfarin and its separated enantiomorphs was evaluated in eight normal subjects. Single oral doses of racemate, S(-)-warfarin, and R (+)-warfarin, were administered in the amounts of 1.5, 0.75 and 1.5 mg per kilogram of body weight, respectively, with and without metronidazole, 750 mg by mouth, beginning seven days before the ...

      Known for Stereoselective Interaction | Warfarin Metronidazole | Prothrombin Time | Single Oral Doses | Blood Coagulation
      KOL-Index: 3920

      The hyperviscosity syndrome is an uncommon complication in IgG myeloma. Its occurrence has been ascribed to the presence in the serum of high molecular weight polymers of the IgG proteins. Three patients with IgG myeloma and the clinical hyperviscosity syndrome were investigated, none of whom had IgG polymers in the serum by analytical ultracentrifugation. Relative serum viscosity in these patients ranged from 10 to 17.4 (normal 1.4-1.8). The total serum proteins ranged from 14 to 19 ...

      Known for Hyperviscosity Syndrome | Igg Myeloma | Blood Viscosity | Molecular Weight | Serum Protein
      KOL-Index: 3044

      In this second reported kindred of hereditary resistance to oral anticoagulant drugs the propositus required 75 to 80 mg of sodium warfarin a day (25 standard deviations above the average dose) to achieve hypoprothrombinemia in the therapeutic range. With this dose, the hypoprothrombinemia could be corrected with daily doses of vitamin K1 of as little as 0.125 mg. Seventeen other family members had an equally resistant response to the oral anticoagulant drugs. The metabolism of sodium ...

      Known for Hereditary Resistance | Oral Anticoagulant | Vitamin Warfarin | Therapeutic Range | Prothrombin Time
      KOL-Index: 2249

      To compare the marked hypoprothrombinemic augmentation in man of racemic warfarin sodium by the pyrazolons phenylbutazone and sulfinpyrazone with that of the coumarin anticoagulant phenprocoumon, these interactions were studied prospectively in six normal subjects. Large single doses of racemic phenprocoumon, 0.6 mg/kg orally, were administered with and without daily phenylbutazone, 300 mg, or sulfinpyrazone, 400 mg, beginning three days before phenprocoumon and continuing for 14 days. ...

      Known for Prothrombin Time | Normal Subjects | Drug Interactions | Male Phenprocoumon | 4 Hydroxycoumarins
      KOL-Index: 1978
      Known for Racemic Warfarin | Stereoselective Interaction | Separated Enantiomorphs | Sulfamethoxazole Trimethoprim | Prothrombin Time
      KOL-Index: 1763

      The article on antithrombotic therapy1 that appeared in the January 23, 1995, issue of the Archives was introduced as a synopsis of the proposed guidelines for an American College of Chest Physicians Consensus Conference on Antithrombotic Therapy, including recent updates and information that will likely influence future recommendations. The authors recommend reversing the anticoagulant effects of warfarin when the international normalized ratio is between 6.0 and 10.0 and "the patient ...

      Known for Vitamin K1 | Warfarin Patient | Publication Administration | International Normalized | Injections Intravenous
      KOL-Index: 1704

      The relationship between the in vitro dissolution kinetics and the in vivo intestinal absorption characteristics of tablet preparations of the coumarin anticoagulant warfarin has been studied. The composition of the dissolution medium had a significant quantitative and qualitative effect on dissolution kinetics. Warfarin absorption in man varied with respect to lag time, absorption rate constants, and the type of kinetics observed. These variations may result from variable gastric ...

      Known for Intestinal Absorption | Ion Concentration | Humans Hydrogen | Anticoagulant Warfarin | Gastric Emptying
      KOL-Index: 1041

      Because daily ingestion of 592 mL of table wine (12% ethanol by volume) during mealtime had no notable effect on long-term, "therapeutic" hypoprothrombinemia with racemic warfarin sodium in normal subjects, similar experiments were repeated using fortified wine (20% ethanol by volume) during fasting. For 21 days, seven normal subjects were given therapeutic levels of the anticoagulant racemic warfarin alone and with warfarin plus 296 mL/day of fortified wine during fasting. The ...

      Known for Table Wine | Anticoagulant Therapy | Prothrombin Time
      KOL-Index: 95

      PRIMARY macroglobulinemia is a systemic disease of many manifestations.1 One of the common complications of the disease is a syndrome consisting of bleeding and ocular and neurologic disorders attributable to hyperviscosity of the blood. The syndrome can be fatal, but with control of the serum macroglobulin level and the hyperviscosity many of the patients show striking clinical improvement.2,3This report describes a case of macroglobulinemia in which an extraordinary increase in the ...

      Key People For Hyperviscosity Syndrome

      Top KOLs in the world
      septic arthritis hyperviscosity syndrome 7s γ1
      John L Fahey
      hyperviscosity syndrome α immunoglobulin reduced synthesis
      Alan Solomon
      bence jones light chains new york city
      Robert A Kyle
      multiple myeloma undetermined significance consultancy funding
      Seema B Singhal
      multiple myeloma speakers bureau hematologic malignancies
      Jayesh Mehta
      multiple myeloma stem cell bone marrow

      Robert A O'Reilly:Expert Impact

      Concepts for whichRobert A O'Reillyhas direct influence:Hyperviscosity syndrome,  Racemic warfarin,  Sodium warfarin,  Stereoselective interaction,  Interaction warfarin,  Plasma albumin,  Hereditary resistance,  Warfarin metronidazole.

      Robert A O'Reilly:KOL impact

      Concepts related to the work of other authors for whichfor which Robert A O'Reilly has influence:Drug interactions,  Oral anticoagulants,  Cytochrome p450,  Enzyme induction,  Warfarin resistance,  Prothrombin time,  Serum albumin.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Department of Medicine, Santa Clara County Hospital, San Jose, and the School of Medicine, University of California at San Francisco

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.